I try to present a reasoned argument why I believe Sarepta would be willing to pay for a solution to a significant problem it faces if it wants to either keep or receive any further marketing approvals for its PMO pipeline– and you respond dismissively by referring to rainbows and peachy posts and stating the bleeding obvious that a deal is needed….
Ann: Successful Competitive Drug Evaluation in Animals, page-14
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
-0.005(4.55%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.0¢ | 10.5¢ | $46.70K | 444.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 987814 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 583624 | 11 |
View Market Depth
| Last trade - 11.30am 12/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |